Morningstar - Ramsay Health Care Limited (RHC) First Steps in Prosthesis List Reform to Impact Manufacturers; Maintaining Ramsay Health Care FVE

Report

Morningstar

Chris Kallos, CFA

EUR 147.86 For Business Accounts Only

First Steps in Prosthesis List Reform to Impact Manufacturers; Maintaining Ramsay Health Care FVE

We maintain our fair value estimate for Ramsay Health Care at AUD 87 per share. Shares in the hospital operator are trading 18% below our intrinsic assessment, and have been adversely impacted by the recent cautious trading update from Healthscope and the release of reform recommendations to the Turnbull government aimed at easing pressure on private health insurance premiums.
These recommendations stem from the final report prepared by the Industry Working Group on Private Health Insurance Pros...

24/10/2016 13 EN

Underlying

Ramsay Health Care Limited

Ramsay Health Care is a global hospital group, which is engaged in providing health care services. Co.'s facilities cater for a range of health care needs from day surgery procedures to complex surgery, as well as psychiatric care and rehabilitation. As of June 30, 2016, Co. operated 223 hospitals and day surgery facilities across Australia, the U.K., France, Indonesia, Malaysia and Italy.

See profile

AU000000RHC8 Australian Securities Exchange Australia

Provider

Morningstar

Morningstar, Inc. is a leading provider of independent investment research in North America, Europe, Australia, and Asia. The company offer an extensive line of products and services for individual investors, financial advisors, asset managers, and retirement plan providers and sponsors.

Morningstar provides data on approximately 530,000 investment offerings, including stocks, mutual funds, and similar vehicles, along with real-time global market data on more than 18 million equities, indexes, futures, options, commodities, and precious metals, in addition to foreign exchange and Treasury markets. Morningstar also offers investment management services through its investment advisory subsidiaries and had approximately $185 billion in assets under advisement and management as of June 30, 2016.

We have operations in 27 countries.

See profile

Analysts

Chris Kallos, CFA

Other Reports on these Companies

SmartInsider

Ramsay Health Care Limited: 3 directors

Three Directors at Ramsay Health Care Limited bought 5,700 shares at between 40.580AUD and 40.722AUD. The significance rating of the trade was 54/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly showing Close periods where trading activity is restricted unde...

Free Trial

September 5, 2024 September 5, 2024 1 EN

TheScreener

With a more favourable environment, RAMSAY HEALTH CARE improves to Slightly Positive

RAMSAY HEALTH CARE (AU), a company active in the Health Care Providers industry, is favoured by a more supportive environment. The independent financial analyst theScreener has confirmed the fundamental rating of the title, which shows 2 out of 4 stars, as well as its unchanged, moderately risky market behaviour. The title leverages a more favourable environment and raises its general evaluation to Slightly Positive. As of the analysis date April 1, 2022, the closing price was AUD 64.45 and its potential was estimated at AUD 70.15.

Free Trial

April 2, 2022 April 2, 2022 1 EN

MarketLine

Healthcare Providers in New Zealand

Summary Healthcare Providers in New Zealand industry profile provides top-line qualitative and quantitative summary information including: market size (value 2017-21, and forecast to 2026). The profile also contains descriptions of the leading players including key financial metrics and analysis of competitive pressures within the market. Key Highlights - The healthcare providers sector is valued as total expenditure on healthcare in each country. This includes final consumption spending on healthcare goods and services. - The New Zealand healthcare providers sector had total revenues of $2...

EUR 446.75

March 23, 2022 March 23, 2022 1 EN

Business as Usual for No-Moat Lonza; Specialty Ingredients Carve-Out on Track for 2020

Contract manufacturer Lonza reported solid half-year results, with over CHF 2.9 billion in total sales year to date, up about 6.4% from last year and boosted by foreign exchange tailwinds. Core EBITDA margin expanded 30 basis points from last year to about 27.8%, helped slightly by new accounting standards. Management indicated that it continues to expect mid- to high-single-digit sales growth in 2019. We are maintaining our fair value estimate of CHF 210 per share and our no-moat rating. The ph...

EUR 100.00

July 25, 2019 July 25, 2019 13 EN

Damien Conover

Damien Conover

Astra Posts Solid 2Q, Driven by Strong Cancer Drug Sales and Moving Away From One-Time Divestments

We don't expect any major changes to our AstraZeneca fair value estimate following second-quarter results that largely fell in line with our expectations and slightly ahead of consensus expectations. Overall, the company is posting leading Big Pharma sales growth with total sales up 18% operationally year over year, led by impressive cancer drug sales growth of 57%. Astra's ability to continue to bring next generation drugs to the market that address unmet medical need (especially in oncology) s...

EUR 100.00

July 25, 2019 July 25, 2019 14 EN

Damien Conover

Damien Conover

Astra Posts Solid 2Q, Driven by Strong Cancer Drug Sales and Moving Away From One-Time Divestments

EUR 100.00

July 25, 2019 July 25, 2019 14 EN

Sign-up for free to access full reports immediately

Email Address*

Choose Password* ( 6 or more characters )

Due to regulatory restrictions regarding the distribution of financial research, this report is restricted to a specific region or investor type. Get access to exclusive reports by answering the questions below.

Select your country*

Get financial insights straight to your inbox

By clicking "register" you accept the Terms and Conditions & Privacy Policy

Already on ResearchPool?

Almost there...

Are you a professional investor?

Select your country

REGISTER

Create a free ResearchPool account to access full reports, get a personalised dashboard and follow providers or companies

In order to access this report please create an account.

LOGIN

First Steps in Prosthesis List Reform to Impact Manufacturers; Maintaining Ramsay Health Care FVE

Ramsay Health Care Limited: 3 directors

With a more favourable environment, RAMSAY HEALTH CARE improves to Slightly Positive

Healthcare Providers in New Zealand

Business as Usual for No-Moat Lonza; Specialty Ingredients Carve-Out on Track for 2020

Astra Posts Solid 2Q, Driven by Strong Cancer Drug Sales and Moving Away From One-Time Divestments

Astra Posts Solid 2Q, Driven by Strong Cancer Drug Sales and Moving Away From One-Time Divestments

Create a free ResearchPool account to access full reports, get a personalised dashboard and follow providers or companies

Sign-up for free to access full reports immediately

ResearchPool Subscriptions

Get the most out of your insights

Why subscribe?

How to subscribe

ResearchPool Subscriptions

This report is only available to subscribers

Why subscribe?

How to subscribe